Previous studies have shown that baseline PD-1+CD8+ T cells [85] and post-treatment CD103+PD-1+CD8+ T cells [86] are positively correlated with longer PFS in GC patients (n = 19 and n = 29) receiving aPD-1 monotherapy. Here, CD8A is linked to gastric cancer.